| Study in Pediatrics With HypEREosinophilic Syndrome (SPHERE) (NCT04965636) | GlaxoSmithKline | 2022-07-14 |
| A Phase III Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES) (NCT04191304) | AstraZeneca | 2020-07-20 |
| Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders (NCT03801434) | William Shomali | 2019-11-15 |
| Natural History of Hypereosinophilia and Hypereosinophilic Syndromes (NCT04018118) | University Hospital, Lille | 2019-05-06 |
| A Multi-center, Open-label Extension, Safety Study of Mepolizumab in Subjects With Hypereosinophilic Syndrome (HES) From Study 200622 (NCT03306043) | GlaxoSmithKline | 2017-11-13 |
| Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES) (NCT02836496) | GlaxoSmithKline | 2017-03-07 |
| Eosinophilia Diagnosis (NCT02581514) | University Hospital, Limoges | 2015-10-01 |
| Study to Evaluate Safety and Efficacy of Dexpramipexole (KNS-760704) in Subjects With Hypereosinophilic Syndrome (NCT02101138) | National Institute of Allergy and Infectious Diseases (NIAID) | 2014-03-14 |
| Steroid Treatment for Hypereosinophilic Syndrome (NCT01524536) | National Institute of Allergy and Infectious Diseases (NIAID) | 2012-02-16 |
| Identification of New Markers in the Hypereosinophilic Syndrome (NCT01713504) | University Hospital, Lille | 2010-06-29 |
| Dasatinib as Therapy for Myeloproliferative Disorders (MPDs) (NCT00255346) | M.D. Anderson Cancer Center | 2005-11-15 |
| A Longitudinal Study of Familial Hypereosinophilia (FE): Natural History and Markers of Disease Progression (NCT00091871) | National Institute of Allergy and Infectious Diseases (NIAID) | 2005-06-08 |
| Efficacy of Imatinib Mesylate in Hypereosinophilic Syndromes (NCT00787384) | Northern Italy Leukemia Group | 2004-10-01 |
| Open-Label Extension Of Intravenous Mepolizumab In Patients With Hypereosinophilic Syndrome (NCT00097370) | GlaxoSmithKline | 2004-09-30 |
| Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes (NCT00171912) | Novartis Pharmaceuticals | 2004-09-01 |
| Intravenous Mepolizumab In Subjects With Hypereosinophilic Syndromes (HES) (NCT00086658) | GlaxoSmithKline | 2004-03-23 |
| Phase II Gleevec Idiopathic Hypereosinophilic Syndrome (NCT00230334) | Steven E. Coutre | 2003-06-12 |
| Study of STI571 in the Treatment of Patients With Idiopathic Hypereosinophilic Syndrome (HES) and Eosinophilic Leukemias (NCT00276926) | University of Bologna | 2003-03-01 |
| Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome (NCT00044304) | National Institute of Allergy and Infectious Diseases (NIAID) | 2002-09-26 |
| A Study to Determine the Safety and Efficacy of Imatinib Mesylate in Patients With Idiopathic Hypereosinophilic Syndrome (NCT00171860) | Novartis Pharmaceuticals | 2002-09-01 |
| Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate (NCT00038675) | M.D. Anderson Cancer Center | 2001-06-01 |
| Anti-Interleukin-5 Antibody to Treat Hypereosinophilic Syndrome (NCT00017862) | National Institute of Allergy and Infectious Diseases (NIAID) | 2001-06-01 |
| This Record Contains Information About the Mepolizumab Compassionate Use (CU) Product Activities: 104317: CU and Long-Term Access Study of Mepolizumab in HES. 201956:A Long-term Access Programme for Subjects With Severe Asthma 112562: Expanded Access for Patients With Hypereosinophilic (NCT00244686) | GlaxoSmithKline | |